May 17, 2018 / 12:43 PM / 2 months ago

BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End

May 17 (Reuters) - Theravance Biopharma Inc:

* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION

* THERAVANCE BIOPHARMA INC - COMPANY EXPECTS TO REPORT DATA FROM AN EXPLORATORY PHASE 2A STUDY IN NOH PATIENTS BY END OF JULY 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below